Arca
Skip to content
Tools
Tools

Label Changes: Xeljanz (tofacitinib citrate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Xeljanz label DailyMed has published, from Pfizer Laboratories Div Pfizer Inc, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 49
  • Sections changed, version 55 to 56: 5, Including the boxed warning

What changed from version 55 to version 56

Sep 28, 2026 to Nov 13, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningChanged · 18 words added, 2 removed
  2. Warnings and precautionsChanged · 27 words added, 3 removed
  3. Clinical studiesChanged · punctuation or symbols only
  4. Patient counseling informationChanged · 35 words added, 58 removed
  5. Medication guideChanged · 126 words added, 66 removed

Boxed warning

Changed18 words added, 2 removed
15 unchanged lines
THROMBOSIS
Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients 50 years of age and older with at least one cardiovascular risk factor treated with XELJANZ tablets 5 mg or 10 mg twice daily compared to TNF blockers had an observed increase in incidence of thesethrombosis. eventsAdditionally, cerebral venous thrombosis (CVT) has occurred in patients treated with XELJANZ and other Janus kinase inhibitors. Avoid XELJANZ/XELJANZ XR in patients at risk. Discontinue XELJANZ/XELJANZ XR and promptly evaluate patients with symptoms of thrombosis [see Warnings and Precautions (5.5)].

Warnings and precautions

Changed27 words added, 3 removed
38 unchanged lines
5.5 Thrombosis
Thrombosis may occur with XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets). Thrombosis, including pulmonary embolism (PE), deep venous thrombosis (DVT), and arterial thrombosis, have occurred in patients treated with XELJANZ and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death [see Warnings and Precautions (5.2)]. Additionally, cases of cerebral venous thrombosis (CVT) have occurred in patients treated with JAK inhibitors, including XELJANZ, in clinical trials and postmarketing.
Patients with RA 50 years of age and older with at least one cardiovascular risk factor treated with XELJANZ tablets 5 mg or 10 mg twice daily compared to TNF blockers in RA Safety Study 1 had an observed increase in incidence of theseDVT, thromboticPE, eventsand arterial thrombosis. The incidence rate of DVT per 100 patient-years was 0.28 for XELJANZ tablets 10 mg twice a day, 0.22 for XELJANZ tablets 5 mg twice a day, and 0.16 for TNF blockers. The incidence rate of PE per 100 patient-years was 0.49 for XELJANZ tablets 10 mg twice a day, 0.18 for XELJANZ tablets 5 mg twice a day, and 0.05 for TNF blockers [see Clinical Studies (14.6)].
XELJANZ 10 mg twice daily (or XELJANZ XR 22 mg once daily) dosages are not recommended for the treatment of RA, PsA, AS, or pcJIA [see Dosage and Administration (2.3 , 2.4) ].
36 unchanged lines

Clinical studies

Changedpunctuation or symbols only
163 unchanged lines
ASAS Components | | | | |
-Patient Global Assessment of Disease Activity (0–10) , | 7.0 | -1.0 | 6.9 | -2.5 | -1.5 (-2.00, -0.97)
-Total spinal pain (0–10) , | 6.9 | -1.1 | 6.9 | -2.6 | -1.5 (-2.00, -1.03)
-BASFI (0–10) , | 5.9 | -0.8 | 5.8 | -2.0 | -1.2 (-1.64, -0.79)
-Inflammation (0–10) , | 6.8 | -1.1 | 6.6 | -2.8 | -1.7 (-2.13, -1.18)
BASDAI Score | 6.5 | -1.2 | 6.4 | -2.6 | -1.4 (-1.86, -0.98)
BASMI , | 4.4 | -0.1 | 4.5 | -0.6 | -0.5 (-0.66, -0.36)
hsCRP , (mg/dL) | 1.8 | -0.1 | 1.6 | -1.1 | -0.9 (-1.17, -0.69)
The percentage of patients with active AS who achieved ASAS20 response by visit is shown in Figure 6.
140 unchanged lines

Patient counseling information

Changed35 words added, 58 removed
9 unchanged lines
Thrombosis
Advise patients to stop taking XELJANZ/XELJANZ XR and to call their healthcare provider right away if they experience any symptoms of thrombosis (sudden shortness of breath, chest pain worsened with breathing, swelling of leg or arm, leg pain or tenderness, red or discolored skin in the affected leg or arm) [see Warnings and Precautions (5.5)].
Advise patients to stop taking XELJANZ/XELJANZ XR and to call their healthcare provider right away if they experience any symptoms of thrombosis, including DVT, PE, or CVT [see Warnings and Precautions (5.5)].
Hypersensitivity
13 unchanged lines
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
LAB-0445-3233.0

Medication guide

Changed126 words added, 66 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: September 2026
MEDICATION GUIDE
7 unchanged lines
4. | Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg or 10 mg twice daily, especially if you are a current or past smoker. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking XELJANZ/XELJANZ XR/XELJANZ oral solution, including: •discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back •severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw •pain or discomfort in your arms, back, neck, jaw, or stomach •shortness of breath with or without chest discomfort •breaking out in a cold sweat •nausea or vomiting •feeling lightheaded •weakness in one part or on one side of your body •slurred speech
5. | Blood clots in the lungs, veins of the legs or arms, and arteries. Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking XELJANZ 5 mg or 10 mg twice daily. Blood clots in the lungs have also happened in people with ulcerative colitis. Some people have died from these blood clots. •StopBlood takingclots XELJANZ/XELJANZcan XR/XELJANZalso oralform solutionin andthe tellveins of the brain (cerebral venous thrombosis [CVT]). •Tell your healthcare provider right away if you develophave signshad andblood symptomsclots in the veins of ayour bloodlegs clot,or suchlungs asin suddenthe shortnesspast. of•Stop breathtaking orXELJANZ/XELJANZ difficultyXR/XELJANZ breathing,oral chestsolution pain,and swellingtell ofyour thehealthcare legprovider or arm,get legemergency painhelp orright tenderness,away orif rednessyou ordevelop discolorationsigns inand thesymptoms legof ora arm.blood clot, including:
| oswelling, redness, weakness or numbness in your arm or leg opain or tenderness in one or both legs onew, unusual, or severe headache otrouble speaking | odrowsiness or confusion osudden unexplained chest or upper back pain oshortness of breath or difficulty breathing oblurry vision, seeing double, or loss of vision
6. | Tears (perforation) in the stomach or intestines. •Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ/XELJANZ XR/XELJANZ oral solution can get tears in their stomach or intestines. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits.
11 unchanged lines
General information about the safe and effective use of XELJANZ/XELJANZ XR/XELJANZ oral solution. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XELJANZ/XELJANZ XR/XELJANZ oral solution for a condition for which it was not prescribed. Do not give XELJANZ/XELJANZ XR/XELJANZ oral solution to other people, even if they have the same symptoms you have. It may harm them. This Medication Guide summarizes the most important information about XELJANZ/XELJANZ XR/XELJANZ oral solution. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about XELJANZ/XELJANZ XR/XELJANZ oral solution that is written for health professionals.
What are the ingredients in XELJANZ 5 mg? Active ingredient: tofacitinib citrate Inactive ingredients: croscarmellose sodium, HPMC 2910/Hypromellose 6cP, lactose monohydrate, macrogol/PEG3350, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. What are the ingredients in XELJANZ 10 mg? Active ingredient: tofacitinib citrate Inactive ingredients: croscarmellose sodium, FD&C Blue #1/Brilliant Blue FCF Aluminum Lake, FD&C Blue #2/Indigo Carmine Aluminum Lake, HPMC 2910/Hypromellose 6cP, lactose monohydrate, macrogol/PEG3350, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. What are the ingredients in XELJANZ XR 11 mg? Active ingredient: tofacitinib citrate Inactive ingredients: cellulose acetate, copovidone, hydroxyethyl cellulose, hydroxypropyl cellulose, HPMC 2910/Hypromellose, magnesium stearate, red iron oxide, sorbitol, titanium dioxide, and triacetin. Printing ink contains ammonium hydroxide, ferrosoferric oxide/black iron, propylene glycol, and shellac glaze. What are the ingredients in XELJANZ XR 22 mg? Active ingredient: tofacitinib citrate Inactive ingredients: cellulose acetate, copovidone, FD&C Blue #2 Aluminum Lake, hydroxyethyl cellulose, hydroxypropyl cellulose, HPMC 2910/Hypromellose, magnesium stearate, red iron oxide, sorbitol, titanium dioxide, triacetin, and yellow iron oxide. Printing ink contains ammonium hydroxide, ferrosoferric oxide/black iron oxide, propylene glycol, and shellac glaze. What are the ingredients in XELJANZ oral solution? Active ingredient: tofacitinib citrate Inactive ingredients: grape flavor (natural), hydrochloric acid, lactic acid, purified water, sodium benzoate, sucralose, and xylitol. This Medication Guide may have been updated. For the most recent Medication Guide, please visit www.pfizer.com. LAB-0535-1819.0
This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: November 2026

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Adverse reactions, Drug interactions, Use in specific populations, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, How supplied, Instructions for use, PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 11 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 22 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 240 mL Bottle Label, PRINCIPAL DISPLAY PANEL - 240 mL Bottle Carton.

Every version

49 versions of set cf74ba2f-afc5-4baa-8594-979c889a5831, newest first.
VersionPublished on DailyMedCompareSPL file
56Nov 13, 2026Shown belowDownload .zip
55Sep 28, 2026With version 54Download .zip
54Jul 15, 2026With version 53Download .zip
53Mar 16, 2026With version 52Download .zip
52Feb 2, 2026With version 51Download .zip
51Nov 17, 2025With version 50Download .zip
50Jun 13, 2025With version 49Download .zip
49Dec 23, 2024With version 48Download .zip
48Nov 27, 2024With version 47Download .zip
47Oct 23, 2024With version 46Download .zip
46Oct 10, 2024With version 45Download .zip
45May 22, 2024With version 44Download .zip
44Nov 28, 2023With version 43Download .zip
43Sep 5, 2023With version 42Download .zip
42May 26, 2023With version 41Download .zip
41Mar 13, 2023With version 40Download .zip
40Nov 30, 2022With version 39Download .zip
39Sep 26, 2022With version 38Download .zip
38Jul 4, 2022With version 37Download .zip
37Feb 18, 2022With version 36Download .zip
36Jan 24, 2022With version 35Download .zip
35Jan 13, 2022With version 34Download .zip
34Dec 20, 2021With version 33Download .zip
33Dec 13, 2021With version 32Download .zip
32Feb 11, 2021With version 31Download .zip
31Nov 24, 2020With version 30Download .zip
30Oct 5, 2020With version 29Download .zip
29Jan 21, 2020With version 28Download .zip
28Sep 13, 2019With version 27Download .zip
27Jul 29, 2019With version 25Download .zip
25Nov 16, 2018With version 24Download .zip
24Oct 29, 2018With version 23Download .zip
23Aug 28, 2018With version 22Download .zip
22Jul 2, 2018With version 19Download .zip
19Dec 20, 2017With version 17Download .zip
17Sep 5, 2017With version 16Download .zip
16Mar 2, 2017With version 15Download .zip
15Nov 15, 2016With version 14Download .zip
14Mar 10, 2016With version 13Download .zip
13Mar 7, 2016With version 12Download .zip
12Jun 26, 2015With version 11Download .zip
11May 16, 2014With version 10Download .zip
10Apr 17, 2014With version 8Download .zip
8Feb 25, 2014With version 7Download .zip
7Nov 20, 2013With version 6Download .zip
6Oct 18, 2013With version 5Download .zip
5Sep 27, 2013With version 4Download .zip
4Nov 13, 2012With version 3Download .zip
3Nov 9, 2012First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.